Study Links Anemia Drugs To Increased Mortality Risk

Law360, New York (February 28, 2008, 12:00 AM EST) -- A group of drugs used to treat anemia in cancer patients undergoing chemotherapy has again been linked to a greater risk of blood clots and death, this time by a study published in the Journal of the American Medical Association.

The study, an analysis of more than 50 separate clinical trials, concluded that patients using so-called erythropoiesis-stimulating agents or ESAs raised their mortality risk by 10%. The study's authors said their findings raised concerns about the safety of prescribing ESAs to cancer patients.

“It looks pretty...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.